UNSPSC 51412903: Ciclonicate

This classification denotes an antilipolytic and a myolytic and nicotinic acid with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H634NXI03, chemically known as 3-pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- but generally known as ciclonicate, which bears US NIH Compound Identifier 68703. European Medicines Agency schedules Ciclonicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06243MIG.

UNSPSC 51412903 Ciclonicate, a Commodity code, covers pharmaceutical supply contracts that state and local governments procure for emergency medical services, public health programs, and institutional care facilities. Recent solicitations show state and local buyers are acquiring specific branded and generic medications—advanced life support drugs, multi-source pharmaceuticals, and over-the-counter products—through sealed competitive bids, RFPs, and cooperative purchasing vehicles that bundle demand across multiple jurisdictions. The work spans direct vendor supply agreements with mandated wholesaler distribution channels, compliance with FDA and cGMP standards, and quality-assurance requirements including expiration-date warranties and product liability coverage.

Issuing bodies range from municipal fire-rescue departments to state health agencies and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited advanced life support medications (epinephrine, labetalol, adenosine, diltiazem) for Tampa Fire Rescue via sealed bid 26P00188, due April 8, 2026, with a $40,000 estimated contract value and a Small Local Business Enterprise set-aside discount of 5 percent. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across member state and local facilities, with proposals due March 26, 2026, and performance through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission posted RFI HHS0017013 on direct-to-manufacturer prescription programs, due April 3, 2026, to assess vendor capability for state pharmacy benefit program support. Recent activity centers in Texas, Minnesota, and Florida, with evidence of ongoing demand across state departments, counties, cities, and interstate cooperative purchasing programs.